 |
 |
Thanks Murray The list of drugs in development at Biospace is quite out of date. A more up to date list of pd drugs in clinical trials (including imaging agents and trials outside the US) was developed by Phil Tompkins for Quadpac's Parkinson-FDA-Industry initiative. (see www.parkinsonscare.org) The List, which can also be found at www.pdindex.org/trials.htm, has approximately 40 compounds on it. Tracking drugs in development is an important component of our efforts to facilitate and enhance the process of evaluation of new drugs. Up to date information is useful not only for patients seeking clinical trials, but also for PWP advisors to both the FDA and individual companies that are developing PD medications. As a first case for tracking, I have been following the development of neuroimmunophilin ligands being developed by Amgen/Guilford. We also need to set priorities for other medications where we might focus our energies. I would like to get input from the PD community on this information. Please provide your opinions and feedback (e.g. more detailed or more up-to-date information) on the medications that you see as high priority for development. For each medication please indicate whether you have taken the medication in a clinical trial, and if so indicate the outcomes for your treatment. We will soon be recruiting for people to act as Research Partners to play an educational role in clinical research settings. Indicate whether you are interested in participating in any way. Send responses to [log in to unmask] Perry Cohen Washington Dc Murray Charters wrote: >Search Clinical Research Studies currently enrolling patients >for Parkinson's disease >http://www.biospace.com/ct/results.cfm?indication=171 > >Cheers ...... murray >[log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn